CLL Topics Banner: Therapies, Research and Patient Education for Chronic Lymphocytic Leukemia
CLL Topics Home Navigation Topics Alert Learning Tools About Us Feedback Feedback
Full Menu

CLL Topics Home Page

  • el
  • pt
  • CLL Topics Updates

    Please read our latest articles at CLL Topics Updates!

    Updates is an interactive site with an emphasis on current developments in the field.

    Most Recent Article:

    News you can use

    Important Notice About this Site

    We suffered a transfiguring loss when Mr. P. C. Venkat, our Editor, Publisher and Chief Financial Officer, passed away from complications after an allogenic cord blood stem cell transplant in June of 2024.

    It took a tremendous effort on his part to keep the non-profit organization running. Without his singular expertise and dedication, we knew we would be unable to fulfill the government regulatory requirements needed to maintain our non-profit status.

    As of 2024, CLL Topics Inc., a non-profit 501(c) was dissolved and all its funds disbursed. We are now operating as CLL Topics LLC, a for-profit company incorporated in the state of Maryland. This, our former flagship site, is being retained on the Web as a resource to the public and to maintain historical continuity but is no longer actively updated.

    We invite you to join us at our new, up-to-date site: CLL Topics Updates. It is an interactive site with an emphasis on current developments in the field.

    We can think of no better testament to his life than to continue our mission in P.C.'s honor — and yours.

    Recently Published

    Older but Important

    Many additional articles can be accessed from the
    Table of Contents


    Topics Alert!

    CLL Topics World Balloon You can read the archives of our Topics Alert service.

    For the latest information on research, clinical trials and best practices — timely information that can make all the difference — please visit our new site: CLL Topics Updates.

    Topics Alert was an email newsletter service offered from March 2024 through December 2024. An Alert went out whenever we had an interesting or important piece of information to communicate. If you would like to read through our archives, they can be seen here:

    Link to the Alert Archive.


    September 3, 2024

    door ornament

    Welcome to
    CLL Topics

    This site is dedicated to providing information and support to patients and families dealing with chronic lymphocytic leukemia (CLL). It takes a clearly patient-oriented view of the world. The subject matter is focused on current developments in understanding and treating the disease.

    Discussion topics include basic science, therapeutic approaches, clinical trials and analyses of the results of these trials. We are witnessing significant changes in our understanding of the processes involved and in the therapies available to combat the disease. It is hoped that the discussions in our articles will bridge the gap between the professional cancer research community and practicing oncologists on the one hand and patients and their families on the other.

    The opinions and analyses presented are those of lay observers of the CLL scene and not those of medical or research professionals. They are not intended to provide clinical guidance or recommendations on the management of the disease. This site draws its strength from a team of dedicated volunteers. None of us has any affiliation with the medical or pharmaceutical industries. Our only interest is patient education and advocacy. We hope our website can help you understand your therapy options better and make you better prepared to discuss these options with your healthcare providers.

    You may use the Contents page to review the material in this site organized by major subject area or use the customized site search form in the right column to get quickly to a specific topic of interest.

    We welcome your comments about this website or your thoughts about any of the subjects discussed or referenced here. Please use the form on our Feedback page or send your email to us at email.

    Chaya & P. C. Venkat


    tree silhouette

    Who Are We?

    CLL was the online publication of a patient-operated, non-profit corporation, CLL Topics, Inc.

    We have no affiliation with any entity in the health care industry and do not accept any advertising on our publication. Our operating expenses were funded entirely by CLL Topics, Inc. which derives all its revenues from donations from the public. The bulk of funds that were raised from our donors was devoted to supporting clinical trials for therapies in CLL. For details, please use links to financial statements and other corporate documents below.

    Please refer to the About Us section on this website for background information on the CLL Topics Team.

    Please do remember that the writers of the articles on are not medical professionals and do not provide medical advice or recommendations for treatment. Please consult and follow the advice of your own healthcare providers.


    Chief Science Writer:
    Chaya Venkat

    Editor, Publisher and Webmaster:
    P. C. Venkat

    Board of Directors:

    L. Keith Friedlander

    Wendy Ramsey

    Chaya Venkat

    P. C. Venkat

    Each member of our Board is a CLL patient or family member of a CLL patient. For short biographies of our Board members, please see the About Us page on this website.


    Press Coverage

    According to Mayo

    You can read an article about CLL Topics and its founders in the Spring 05 issue of Mayo Magazine: Information Empowers Leukemia Patients

    According to
    the Wall Street Journal

    The Journal, too, has had occasion to publish an article in which CLL Topics figured. You can read the March 2024 article by Journal reporter Rhonda Rundle at: Testing the Power of Green Tea.

    According to
    the Washington Post

    The Washington Post was not far behind in publishing an article in which CLL Topics received positive coverage. You can read read why their reporter says, "For the latest real news specific to the condition, I would find the best stuff on CLL Topics." Here is a link to the Post article, A 10-Year Checkup. If you find this link does not work, write to us and we will help you locate one that does.


    Zen Sunset

    Our Non-Discrimination Policy

    We Support CLL Patients Everywhere - and Bar None

    CLL Topics extends its services to and encourages participation in its activities by all individuals affected by Chronic Lymphocytic Leukemia. It does not discriminate on the basis of race, ethnicity, religion, age, size, national origin, citizenship, geographic location, language, gender, sexual orientation, socioeconomic background or mental or physical handicap. In fact, we are pleased to extend our services to any person who wishes to benefit from them.


    An Open Invitation

    Exercise Your Pen - or Keyboard

    Your Opinion Counts

    The CLL Topics Team is happy to hear from you. We value your willingness to share your knowledge, experience and concern for our community. The section titled "Patients' Corner" is intended to provide a forum for your opinions and insights. Of course, your articles can be published in any of the other sections if they fit better there. If you would like us to consider for publication an article you have written, please submit the document by email to the address shown below.

    Don't forget to include your name and email address or phone number so that we can contact you if we have any questions. We will entertain full-length articles, announcements or snippets of information or commentary that may be of interest to our readers.

    — Editor

    Volunteer Patient Support Groups

    You will find links to a number of patient education and support groups on our page dedicated to Support Groups.

    Navigating Topics

    Help to Get the Most Out of This Site

    It's Easier Than You Think

    The sheer amount of information available on this site may be overwhelming at first. But appearances can be deceptive, especially in this case. Most people find that there are some easy ways of getting around the site, locating topics of interest, printing the material they want as hard copies, downloading material and solving technical problems as they arise. We have paid special attention to browser compatibility, accessibility and ease of use. Many of these subjects are covered in our Navigation Notes article.

    Of course, we can always use your help to identify those areas which have still escaped our attention, or simply those that do not work right for you. Just write to us with a clear explanation of the problem and include the basic details of your computer set-up. It is entirely possible that someone else has run into your particular problem and we may already have an off-the-shelf solution. We do not promise to cure all the technical ills of the world wide web. We will, however, listen to your problems politely and at least try to make helpful suggestions. After all, we would like to make our work accessible to as many people as possible. That's why we started Topics in the first place.

    Steelfoil Lillies

    Key Pointers

    The Contents page will provide you with links to all the main subject areas on this website dealing with the disease, its diagnosis, prognosis, therapies, clinical research and the societal aspects of coping with the disease and the medical establishment.

    A CLL Primer is directed at newly diagnosed patients (or as a refresher for those desiring to get caught up quickly) and serves to orient the patient or caregiver and highlight some basic facts and considerations. A list of additional articles to read is suggested in Step 5.

    You will find spreadsheet templates you can use to keep track of your clinical data in Your Charts.

    Our Reference section has links to many important resources on the Web for patients seeking to expand their knowledge of the disease.

    For those with a scholastic bent, the Textbooks section provides links to a collection of superb online textbooks that can provide an entire education.

    The Search Tools page gives you access to professional search tools to locate abstracts and articles, search scientific databases, medical news and clinical trials.

    Donations: Your generous support and encouragement have been terrific. You have indeed shown us that you think what we do is worthwhile. With your help we have exceeded our fundraising goals for the year. As of July 1, 2024 we are temporarily suspending our fundraising. This also happens to be the time when our editor, publisher, webmaster and record keeper is going into a chemoimmunotherapy treatment program - and suspending fundraising will enable us to concentrate our resources on running our publishing operation (this website and Topics Alert). Send us an email (email) if you would like to volunteer your time and skills to join us in the work of this organization.

    About Our Articles

    Please do browse Current Articles and Contents to orient yourself to the resources available on this site. The material presented is based on serious, peer-reviewed articles in professionals and scientific journals, complete with references and links to source materials. However, we have made it a priority to simplify the language and clarify the communication to make it accessible to the lay reader. Most important, we offer critical review form the patient's point of view. We hope you will become familiar with the terminology, our style of presentation and the navigation of this website pretty quickly. If you do experience difficulty with any part of it, please send us your comments so that we may improve this website. You may use the form on our Feedback page or send email to email.


    Company News

    CLL Topics becomes a Corporation.

    A Short History

    This website, CLL, has been on the Web for a relatively short time. It was launched on April 4, 2024.

    CLL Topics, Inc. was registered as an Arizona non-profit corporation on October 27, 2024. The IRS issued an advance ruling on the Corporation's 501(c)(3) tax-exempt status on June 21, 2024.

    On December 16, 2024 the collaboration with Mayo Clinic on Project Alpha was announced. As of December 16, 2024, the Corporation started fundraising to support clinical trials. For more details please see our Donations page.

    On February 25, 2024, the IRS confirmed its advance ruling that CLL Topics, Inc. is a public charity, having conformed to all regulatory requirements for this status. As of March 1, 2024, the Corporation has finished five years of regulatory reporting, raised over $300,000 in funds from worldwide donations principally for supporting clinical research in CLL, sponsored and funded four clinical trials with a fifth in the final stages of regulatory approval and maintained an active online publication and bulletin system in the form of and Topics Alert. On February 25, 2024, we launched an online journal focusing on the details of a cord blood stem cell transplant for a CLL patient.

    ornate embroidery

    Summary of Projects and Fundraising:

    As of December 31, 2024 we have received a total of $310,828.34 from 555 donors. For details and a list of donors, please see our Acknowledgements page.

    We have fully funded our commitments to three clinical trials that we have sponsored, and another two are pending disbursement. Current fund balances will support investigations of a number of promising new agents. Additional details will be reported as we develop these projects with the research community. You can read the details of past projects we have sponsored on the page on Sponsored Projects. Your donations have enabled us to offer critical  financial support to these investigations at a formative stage and demonstrate patient involvement and reflect patient priorities in the process.

    We have reached our fundraising goals for the year 2024 and as of July 1, 200 we will temporarily suspend fundraising activities while our publisher, webmaster and chief administrator is undergoing treatment for his CLL. Suspending this labor-intensive activity will lighten up our operational commitments and allow us to concentrate our time and effort on maintaining our publishing and educational activities, including this website and Topics Alerts. We will report on the results from our sponsored projects as and when they become available.

    We are grateful to all our generous donors for their support and encouragement.

    FLW art glass

    Transparency and Accounting

    Financial Statements csgo betting

    To see financial statements for the Corporation you may use the following links:

    Fiscal 2024 Statement;

    Fiscal 2024 Statement;

    Fiscal 2024 Statement;

    Fiscal 2024 Statement;

    Fiscal 2024 Statement.

    Other Corporate Documents

    Additional corporate information may be found through the following links:

    Annual Report to the Board for 2024;

    Annual Report to the Board for 2024;

    Annual Report to the Board for 2024;

    Annual Report to the Board for 2024;

    Articles of Incorporation;


    Ruling Confirming Status as Public Charity;

    IRS Tax Exemption Letter;

    Application for Tax Exemption;

    Arizona Secretary of State Filings;

    Arizona Corporation Commission Filings.


    Our Site Is Standards Compliant

    Valid XHTML 1.0 Transitional Valid CSS!
    museum alcove


    Useful Tools:


    Google Logo

    Both search forms shown here will return results from customized searches of this website. The Google search form above produces results unencumbered by sponsored ads, while the search results from the Atomz engine below come with sponsored ads which some will find annoying. However, it has the advantage of more frequent indexing and a more up-to-date database — so you are more likely to find material recently added to the website.

    Atomz Logo

    There is also an advanced search form for more complex searches. You are encouraged to experiment with these search tools.

    Copyright Notice

    All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.

    However, you may download and print material from exclusively for your personal, noncommercial use.

    Copyright © 2024 to 2024.
    CLL Topics, Inc.
    All Rights Reserved.





    Αριστοκράτης Καζίνο / Φέρνοντας Ποιότητα Κουλοχέρηδες Από Το 1953 Ο αριστοκράτης είναι ο δεύτερος μεγαλύτερος κατασκευαστής Κουλοχέρηδων στον κόσμο για καζίνο γης και προσφέρει μια πολύ υψηλής ποιότητας συλλογή διαδικτυακών παιχνιδιών. /aristocrat Αριστοκράτης καζίνο καινοτομία υποστηρίζεται από την εμπειρία

    Η Jo είναι μια έμπειρη και σεβαστή αρχή στον κλάδο των τυχερών παιχνιδιών, που κατέχει σχεδόν δεκαπέντε χρόνια αφοσιωμένης εμπειρίας γραφής. Ειδικευμένος στον τομέα των online καζίνο, ο Jo έχει συγκεντρώσει εκτεταμένη εμπειρία, καθιερώνοντας τον εαυτό του ως γνώστη στην αναγνώριση και αξιολόγηση παιχνιδιών και πλατφορμών υψηλής ποιότητας.μέσω της δέσμευσής του στον κλάδο, ο Τζο ενημερώνεται επιμελώς για τα τελευταία νέα, τις τάσεις και τις εξελίξεις στον κόσμο των τυχερών παιχνιδιών. Αυτή η ολοκληρωμένη γνώση και αφοσίωση μεταφράζεται στην παροχή αξιόπιστων, έγκυρη καθοδήγηση και γνώσεις στους παίκτες.το πάθος του Τζο έγκειται στην αξιοποίηση της εμπειρίας του για να ενδυναμώσει τους παίκτες, εξασφαλίζοντας ότι απολαμβάνουν τις καλύτερες εμπειρίες σε κορυφαία διαδικτυακά καζίνο. Αυτή η συνεχής συνεισφορά υπογραμμίζει το ανάστημα της Τζο ως ηγετική φωνή και αξιόπιστη πηγή στον κλάδο των διαδικτυακών τυχερών παιχνιδιών.

    Email: [email protected]




    Topic: CLL Topics Home

    Topics Search
    Enter Keywords:


    Newly Diagnosed?


    Read A CLL Primer

    Discover What Type of CLL you have;

    Read through our Topics Alerts Archive;

    Organize and maintain Your Charts;

    Get to know the recommended Best Practices for dealing with CLL;

    Become an informed customer before you go Shopping for Therapies or sign up for a clinical trial.


    We have an online journal detailing the background and stages of a cord blood stem cell transplant for our case study patient, Harvey. Please do visit.

    Clinical Research
    Sponsored by
    CLL Topics

    Ever wonder what we do with the money we raise from your donations? cassino online

    You can read about the clinical trials we have sponsored by clicking here: CLL Topics Sponsored Clinical Trials.

    We explain the thinking behind these projects in an article titled Our Sponsorship Philosophy.


    Open Clinical Trials

    Editorial from the New England Journal of Medicine

    October 3, 2024

    “ … It is time for participants in clinical trials to take the initiative. People interested in participating in trials should consider only studies whose sponsors have fully registered them in an appropriate public database and agreed to publish their results.

    We agree. The full editorial is available in pdf form at the NEJM website. Patients are encouraged to read the editorial and understand the issues involved since they are critically important for individual participants in clinical trials as well as for the entire patient community.

    Ivy League Sepia

    Thanks to dedicated clinical researchers and brave volunteers enlisting in clinical trials, diagnostic tools and therapy options are changing fast in the treatment of CLL. We hope to assist you in understanding the type of CLL you have, the therapy options out there and some of the basic considerations in choosing how to proceed. The expression “living to fight another day” gains a special meaning when the whole ball game may change tomorrow.

    Here are some of the therapies and agents we have discussed in our past articles:

    Please do remember that the writers of the articles on are not medical professionals and do not provide medical advice or recommendations for treatment. Please consult and follow the advice of your own healthcare providers.

    Greek Column


    Status of Fundraising

    World Money and Globe

    We have reached our fundraising goal for 2024 and as of July 1, 2024 we are temporarily suspending our fundraising efforts. You can look up where we are in our fundraising both on the Donation Status page and the Acknowledgements page on this site. We are proud to acknowledge the generous gifts of many who support us in our work.

    Managing Infections

    In our Reference section you will find a valuable new addition on managing infections in the immune compromised patient. There is extensive material of particular relevance to CLL patients.

    Patients' Corner

    In our section called Patients' Corner, you can read other patients' opinions on diverse topics.

    Physicians' Corner

    In our section called Physicians' Corner, you will find articles and correspondence from physicians, researchers and other experts. Dr. Andrew Pettitt of the Royal Liverpool Hospital discusses the use of steroid-Campath combinations in p53-deleted cases. In Are We There Yet? you can read an article by Professor Terry Hamblin evaluating the progress made to date on finding a cure for CLL. In another article, Dr. Tim Call, a specialist at Mayo Clinic, Rochester, MN offers some facts and insight into the difficult subject of Familial CLL.

    Herbs and Supplements

    In our Reference section you will find a new link to a valuable resource from Memorial Sloan-Kettering on herbs, botanicals and other products.

    The Virtues of Green Tea

    In the section on Phytochemicals, Nutrition and Chemoprevention, you will find an article discussing the anti-cancer activity of green tea polyphenols: Do You Like Drinking Green Tea?

    Vitamin D

    Vitamin D3 or cholecalciferol has multiple functions in human physiology. Some of these functions are critically important in preventing and fighting infections, inflammation and even cancers. Traditionally, the value of this vitamin has been greatly underappreciated — and traditional dosage guidelines are now viewed by experts as seriously inadequate. The risk of hypercalcemia (a serious and even fatal condition) comes into play at high dosage rates: an issue to be carefully considered. There is an impressive body of credible research supporting the new viewpoint. The Vitamin D Council is a well-organized website with comprehensive information on the topic, presented in a straightforward way that patients can understand. The experts behind this organization have impressive credentials. Please do visit this site and read the material presented to decide for yourself whether Vitamin D3 supplementation should be a part of your regimen.

    Of course, we have our own collection of articles and Alerts on the subject of Vitamin D3 and its importance in CLL. You can find links to the entire collection on our Vitamin D3 page, or start by reading the article below.

    Vitamin D3: Essential for Health

    Dosages, Cautions and the Need for Monitoring

    Effective Supplementation Can Help Fight Cancer

    spiral Vitamin D is a very potent regulator of cellular biochemistry. We review the research literature on the value of an adequate intake of Vitamin D3 in maintaining general health and in fighting cancer. The literature indicates that the officially recommended dosage (RDA) of the vitamin is barely enough to avoid deficiency diseases and woefully inadequate to provide the multiple health benefits available from this supplement. However, any aggressive supplementation regimen must be carefully monitored and medically supervised since high dosages can lead to systemic toxicity (hypercalcemia) and even death. Our review article, “Vitamin D3: Essential for Health” explores the benefits, raises the caution flags and explains how to benefit from the vitamin without the risk of sun exposure.




    The Price of
    Military Service

    VA Accepts the Agent Orange Connection to CLL

    Veterans Please Note –
    Court Ordered Retroactive Benefits

    Our Agent Orange Update should be of interest to veterans and others interVietnamested in the scientific evidence of the connection between CLL and Agent Orange and in the formal statements of the VA's approach to this subject.

    You can read a recent (April 2024) email on how the VA is treating AO veterans.


    Mayo Best Practices

    Current Approach to Diagnosis and Management of CLL

    What You and Your Oncologist Need to Know about CLL

    mayo building We review and comment on an important new paper from the Mayo Clinic Hematology Team. Authors Shanafelt and Call provide an extremely useful review of recent changes in diagnostic methods and risk assessment and their therapeutic implications for various cytogenetic sub-categories of CLL. This is a must-read paper for both you and your local oncologist. Our editorial comment examines areas in which they could have gone farther in their recommendations. Click here to read "Need to Know".

    What Type of CLL Do You Have?

    Analyzing CLL by Risk Categories

    Defining Risk "Buckets" as a Framework for Therapy Decisions

    multicolor fixture This article, "What Type of CLL Do You Have?", is a detailed review of a number of important CLL prognostic indicators. It explores a concept for combining the available indicators to assess progression risk in a given case, grouping patient into buckets A, B and C. A higher risk category poses trickier problems in picking a treatment strategy but modern therapeutic options do offer usable approaches.

    FISH-ing for Answers

    Chromosomal Aberrations Rule the Game

    Getting Your FISH Test Done

    fish FISH (fluorescence in-situ hybridization) testing can provide key information to CLL patients and their doctors in making therapy decisions. In " FISH-ing for Answers" we provide some critical information that may be useful in getting your very own FISH test done.

    Familial CLL

    Genetic Predisposition and Anticipation

    To Know or Not to Know: That Is the Question

    ducks Not the Worst Day of Your Life is a review of the research findings on the familial aspects of CLL. It is well documented that CLL strikes more than one person in some families, there is clearly a predisposition to the disease that has been passed on from one generation to the next in these families. In addition, the data show that in families where the disease strikes more than one generation, the children of a CLL patient are likely to be diagnosed with the disease at an younger age compared to the parent. Finally, we discuss some of the difficult issues involved in testing children for potential genetic problems.

    Campath - Looking Better and Better

    Campath Proves Effective in Early Stage and Difficult Cases

    Experts Get Better at Using the Anti-CD 52 Monoclonal

    Campath molecule We review the current status of research and clinical trials involving Campath-1H. This fully humanized monoclonal antibody has been approved by the FDA for use in relapsed CLL but current research reveals that it could have critical application as a frontline therapy in a subset of high risk cases. It is a powerful therapeutic agent that is slowly finding wider applicability in early stage patients. The techniques of administration have improved and so have the techniques of managing the serious immune suppression attendant to its use. Our review article, Campath Looking Better and Better, explores these and other aspects of Campath therapy.

    Prognostic Indicators

    Using Modern Tools

    Prognosis at Diagnosis - Integrating Molecular Biologic Insights into Clinical Practice

    flow cytometry We examine a critically important new Blood First Edition Paper in Prognosis at Diagnosis, our review of the article of the same name from the experts at Mayo Clinic. While much of the research quoted in their paper has been previously reported, what makes the paper unique is that it puts it all together in one irrefutable package: the research, the results, the logic, the recommendations. I have no doubt this paper will be one of the most influential papers in CLL, and will be influencing clinical practice for many years to come."

    Chemotherapy Insight

    The "How" Is Often as Important as the "What" in Chemotherapy

    Methods of Drug Delivery

    lymphatic system Physiology offers some insights into the effectiveness of various methods of drug delivery. The same drug can have different effects (and side effects) when administered using novel techniques. You will find our discussion of this subject in The "How" Is Often as Important as the "What".

    Adhesion, Homing and Resistance

    Why Peripheral Blood Numbers Do Not Tell the Whole Story — and Why CLL Cells Are Hard to Kill.

    It's a Tale of Adhesion Factors, Chemokine Trails, Receptors and Blockers

    cell micrograph Cellular chemistry drives the behaviour of CLL and determines the characteristics of the different clonal subtypes. We examine a number of critical aspects such as resistance to therapies, bulkiness of lymph nodes, infiltration of bone marrow and the support structure for CLL cells in their preferred environments. We also look at some futuristic possibilities for therapies in this article, Adhesion, Homing and Resistance to Therapy.


    Role of the ATM and TP53 Genes in Disease Progression and Response to Therapy

    The Science Behind the Grim Statistics Offers the Hope of Better Therapeutic Strategies

    gene plot The TP53 gene and the ATM gene play a critical role in the behavior of CLL cells. We explore the roles of these genes in the life of a normal cell and their malfunction in cancer. Modern FISH analysis focusing on these genes helps identify the risk characteristics and aggressiveness of a given patient's CLL and is therefore an important prognostic tool. Click here to read Cytogenetics of ATM and TP53.

    Chronic Pulmonary Inflammation

    Major New Study Indicts Role of Pulmonary Inflammation

    Deadly Feedback Cycle of Inflammation and CLL

    cell micrograph Widespread anecdotal evidence suggesting pulmonary complications are a major factor in CLL is now supplanted by solid statistical data reported in an article in the journal Cancer by a team led by Dr. Kanti Rai at the Long Island Jewish Medical Center. They confirm that pneumonia is by far the leading cause of mortality and morbidity for CLL patients – and the leading pulmonary complication among patients hospitalized with CLL. Our article, Role of Pulmonary Inflammation in CLL, examines the relationships involved and implications for therapy.

    Dying to Get a Tan?

    The Danger of Squamous Cell Carcinoma in CLL Patients

    Things You Can Do to Avoid SCC

    sunsquare If you have CLL, you have a much higher chance of getting squamous cell carcinoma (SCC), the second most common skin cancer. Further, CLL patients who contract this disease are more likely to have an aggressive form of the disease. We examine some of the possible mechanisms for the onset of this cancer and review a number of steps you can take to protect yourself including a few things you can discuss with your doctor that may help. Click here to read Dying to Get a Tan?

    Target Mitochondrion

    Promising New Approaches May Level the Playing Field for Bucket C Patients

    Attacking Mitochondria in B-CLL Cells

    mitochondrion Several recent research articles have opened up exciting new opportunities in the treatment of CLL. These feature new small molecule drugs that take an entirely different approach to targeting CLL cells, bypassing the usual cellular control points. In this new approach to treating CLL, it seems to make no difference if you are IgVH mutated or unmutated, CD38 positive or not, chemo-naïve or have been through the wars with every chemotherapy drug known to man. In fact, there are some indications that heavily pretreated and late Rai stage patients may respond better to this approach. To learn more, read Exciting New Drugs on the Horizon.

    AIHA: Auto-Immune Hemolytic Anemia

    Important Insight

    Causes, Mechanisms & Therapeutic Strategies

    RBCs AHIA affects a significant part of the CLL population, particularly those with advanced disease. Understanding the causes of the disorder is critical to dealing with it. In AIHA: Auto-Immune Hemolytic Anemia, we review the relevant research and make some suggestions.

    Side Effects

    EPO Linked to Promotion of Angiogenesis, Tumor Growth and Shorter Survival

    The Dark Side of Epoetin

    EPO A very recent study casts light on some negative aspects of epoetin therapy. In addition to the desired effect of a rapid increase in red blood cells and hemoglobin and an improvement in quality of life, these drugs have now been shown in a carefully designed study to promote significant angiogenesis and tumor growth. Our article, The Dark Side of Epoetin, gives you an overview of the research on this aspect of an important supporting therapy.

    Chronic Inflammation

    What You Can Do

    Interaction between CLL and Chronic Inflammation

    inflammation Sinus problems got you down? Here are some conclusions from recent research in cellular biochemistry. The good news is that the linkage between inflammation and CLL offers a hint for a new therapeutic approach. You can read about it in the article CLL, Chronic Inflammation and What You Can Do About It.

    Disease Characteristics

    Nature of CLL

    Clonal Evolution: How the Disease Grows and Evolves

    evolution diagram In this article we review important new research into the mechanisms by which clonal B-CLL cells become more aggressive and harder to kill. This is Darwinian selection at the cellular level. We look at the implications for treatment strategy and offer a new approach to managing the disease in Clonal Evolution.


    Case of
    the Round-Headed

    Notes on a Difficult Case

    Things Are Never Easy for the Round-Headed Kid.

    Choices are Trickier for Patients with Poor Cytogenetic Aberrations

    companions Lucy may never have given Charlie Brown that perfect opportunity to kick a field goal, but we give our own round-headed hero, Harvey, a hand in figuring out what to do when he gets some bad news on the cytogenetics front. Faced with a 11q deletion event, our hero gets down to facing the facts and grappling with some thorny questions. The saga starts with The Difficult Case of the Round-headed Kid — and continues over a number of installments as our hero faces therapy decisions and disease complications. You will find the entire series of articles in our RHK Saga.





    Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.

    Copyright Notice:

    Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.

    All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.

    However, you may download and print material from exclusively for your personal, noncommercial use.


    bästa casino online